Apellis Pharmaceuticals I...

NASDAQ: APLS · Real-Time Price · USD
27.77
0.15 (0.54%)
At close: Aug 15, 2025, 3:59 PM
28.85
3.91%
After-hours: Aug 15, 2025, 04:56 PM EDT

Apellis Pharmaceuticals Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
411.29M 351.19M 551.8M 640.19M
Short-Term Investments
n/a 1.11M 6.5M 60.36M
Long-Term Investments
n/a 3.24M n/a n/a
Other Long-Term Assets
77.06M -1.93M 15.8M 31.64M
Receivables
271.72M 206.44M 7.73M 10.1M
Inventory
81.4M 146.36M 85.71M 16.29M
Other Current Assets
6.17M 22.41M 36.66M 72.24M
Total Current Assets
788.95M 766.33M 719.52M 824.05M
Property-Plant & Equipment
19.04M 21.09M 24.89M 26.08M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
96.1M 22.4M 40.69M 57.72M
Total Assets
885.05M 788.73M 760.22M 881.76M
Account Payables
38.57M 37.52M 37.34M 16.91M
Deferred Revenue
n/a n/a n/a 103.24M
Short-Term Debt
6.75M n/a n/a n/a
Other Current Liabilities
140.18M 75.83M 81.43M 7.58M
Total Current Liabilities
185.51M 247.59M 167.61M 131.85M
Long-Term Debt
452.83M 93.03M 92.74M 189.02M
Other Long-Term Liabilities
7.97M 242.13M 315.65M 345.15M
Total Long-Term Liabilities
471M 346.62M 422.74M 551.26M
Total Liabilities
656.51M 594.21M 590.35M 683.1M
Total Debt
469.78M 110.93M 112.71M 210.22M
Common Stock
12K 12K 11K 10K
Retained Earnings
-3.04B -2.84B -2.31B -1.66B
Comprehensive Income
-3.31M -3.54M -875K -2.09M
Shareholders Equity
228.54M 194.52M 169.87M 198.66M
Total Investments
n/a 4.35M 6.5M 60.36M